Pharmacy First's Five New Conditions and What to Get Ready First

NHS England confirmed this month that five new conditions are being added to the Pharmacy First independent prescribing pathways from this autumn, acute otitis externa in adults, seasonal allergic rhinitis in children, mild to moderate acne, low frequency episodic migraine, and mild skin and soft tissue infections including scabies. It's backed by £340 million and the maths reckon it could mean two to three million extra consultations a year once it's properly up and running, on top of the fourteen million Pharmacy First has already delivered since it launched back in February 2024. On paper it's a big vote of confidence in what community pharmacy and independent prescribers can do.

What caught my eye reading the announcement wasn't the conditions themselves, it was Community Pharmacy England's own response alongside it, which said plainly that more guidance and documentation on prescribing within the contract is still to come, and that if this is going to work at scale it needs to be backed by proper investment in clinical governance and infrastructure, not just funding for the service itself. That's a fairly candid thing for a negotiating body to say about its own announcement, and it's worth pharmacies taking it seriously rather than waiting to see what turns up.

I spent a good few years as a GPhC inspector walking into pharmacies that had switched a service on, and the gap between "we're now offering this" and "we've actually got the SOP, the training records, and the escalation pathway written down" is usually where the trouble starts. An independent prescriber taking on migraine or acne consultations needs more than the clinical competency to prescribe for it, they need a pharmacy that can show how referrals in and out are handled, what happens when a red flag symptom turns up in what looks like a routine consultation, and how that's all recorded so it stands up if anyone ever asks. None of that requires waiting for NHS England to publish anything else, it's the same groundwork any advanced service needs and most pharmacies already know how to do it, it's just easy to let it slip when the clinical side of a new pathway is the exciting bit.

I wrote a bit about the wider shift towards independent prescribing back in an earlier post, and this feels like the next practical step of that same conversation, prescribing volume is going up faster than the supporting guidance, so the governance has to come from the pharmacy itself in the meantime. If you're planning to start offering treatment for any of these five conditions this autumn, I'd start thinking about the clinical pathway before the first patient walks in.

NHS England announce the new Pharmacy First prescribing pathways — Community Pharmacy England, 10 September 2026